Cargando…
Dapagliflozin reduces pulmonary vascular damage and susceptibility to atrial fibrillation in right heart disease
AIMS: Sodium‐glucose cotransporter 2 inhibitors (SGLT2is) have made considerable progress in the field of heart failure, but their application in arrhythmia remains to be in‐depth. Right heart disease (RHD) often leads to right heart dysfunction and is associated with atrial fibrillation (AF). Here,...
Autores principales: | Dai, Chang, Kong, Bin, Shuai, Wei, Xiao, Zheng, Qin, Tianyou, Fang, Jin, Gong, Yang, Zhu, Jun, Liu, Qi, Fu, Hui, Meng, Hong, Huang, He |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871681/ https://www.ncbi.nlm.nih.gov/pubmed/36369767 http://dx.doi.org/10.1002/ehf2.14169 |
Ejemplares similares
-
Protective effects of Dapagliflozin on the vulnerability of ventricular arrhythmia in rats with pulmonary artery hypertension induced by monocrotaline
por: Qin, Tianyou, et al.
Publicado: (2022) -
Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF
por: Butt, Jawad H., et al.
Publicado: (2021) -
Dapagliflozin reduces the vulnerability of rats with pulmonary arterial hypertension-induced right heart failure to ventricular arrhythmia by restoring calcium handling
por: Wu, Jinchun, et al.
Publicado: (2022) -
Right atrial appendage: an important structure to drive atrial fibrillation
por: Liu, Yang, et al.
Publicado: (2022) -
USP38 exacerbates atrial inflammation, fibrosis, and susceptibility to atrial fibrillation after myocardial infarction in mice
por: Gong, Yang, et al.
Publicado: (2023)